Deals
While Novartis secured the biggest deal of the fourth quarter, a handful of riveting tales emerged from the bottom of the M&A list, including a zombie buyout and a bidding war. And no, we’re not talking about Metsera.
FEATURED STORIES
2026 is set to be a banner year for M&A in biopharma, as buyers facing major patent cliffs fight for a small pool of late-stage assets.
Metsera showed the biopharma world that M&A is back. Who could be next?
These deals radically reshaped the biopharma world, either by one vaccine rival absorbing another, a Big Pharma doubling down after another failed acquisition or, in the case of Pfizer and Novo, two heavyweights duking it out over a hot obesity biotech.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Using a combination of machine learning and parallel chemistry to change the way we think about treating disease
The dermatological drug maker will use Chapter 11 protection to restructure the company, including a possible sale of assets, and will delay development of its Phase III-ready psoriasis treatment.
CARB-X is awarding Procarta Biosystems, a UK-based biotech company, up to US$2.2 million in non-dilutive funding with the possibility of $7.0 million more if certain project milestones are met, to develop a new class of antibiotics to treat Gram-negative ESKAPE pathogens.
CMR Surgical Limited announces that it has raised £195 million ($240 million) to fully fund the global commercialisation of the business.
Race Oncology Limited is pleased to announce that prominent biotechnology investor and substantial Race shareholder, Dr Daniel Tillett, has joined the Board of Directors of Race Oncology Ltd.
Khanu Management GmbH, a drug discovery focused fund management team, announces the successful launch of KHAN Technology Transfer Fund I GmbH & Co KG, based in Dortmund, Germany.
New facilities expand services offering to Irish and International customers
Horizon Discovery Group plc announces its results for the six months ended 30 June 2019.
Satsuma Pharmaceuticals, Inc. has announced the pricing of its initial public offering of 5,500,000 shares of common stock at a public offering price of $15.00 per share, for gross proceeds of $82.5 million, before the underwriting discounts and commissions.
Lundbeck announced the acquisition aimed at eptinezumab, Alder’s investigational monoclonal antibody (mAb) for migraine prevention targeting the calcitonin gene-related peptide that has been submitted to the U.S. Food and Drug Administration for potential approval.